Association of Preoperative EpCAM Circulating Tumor Cells and Peripheral Treg Cell Levels with Early Recurrence of Hepatocellular Carcinoma Following Radical Hepatic Resection
Overview
Authors
Affiliations
Background: This study was carried out to determine the prognostic significance of preoperative peripheral epithelial cell adhesion molecule- positive (EpCAM (+)) circulating tumor cell (CTC) and T regulatory (Treg) cell levels in hepatocellular carcinoma (HCC) patients for the prediction of postoperative recurrence following curative resection.
Methods: A total of 49 patients about to undergo curative resection for HCC were recruited into the study. PCR and FACS were used to detect the preoperative levels of EpCAM (mRNA+) CTCs and CD4(+)CD25(+)Foxp3(+) Treg cells. The prognostic value of EpCAM (mRNA+) CTCs, CD4(+)CD25(+)Foxp3(+) Treg cells, and other clinicopathological factors were analyzed by applying the Kaplan-Meier method and the multivariate Cox proportional hazards model.
Results: The number of EpCAM (mRNA+) CTCs and Treg/CD4(+) cells showed significant correlation as prognostic factors of postoperative HCC recurrence: EpCAM (mRNA+) CTC ≥ 2.22 (P = 0.001) and Treg/CD4(+) ≥ 5.07 (P = 0.045), with EpCAM (mRNA+) CTC ≥ 2.22 (P = 0.003, HR = 6.668) being the most important indicator. Patients with high CTC/Treg levels showed a significantly higher risk of developing postoperative HCC recurrence than those with low CTC/Treg levels (66.7 % vs. 10.3 %, P < 0.001). The high CTC/low Treg group also presented higher 1-year recurrence rates compared with the low CTC/low Treg level group (50.0 % vs. 10.3 %, P = 0.004).
Conclusions: Elevated EpCAM (mRNA+) CTC and Treg/CD4(+) levels were associated with early recurrence of HCC, indicative of poor clinical outcome. The combined detection of EpCAM (mRNA+) CTC and Treg/CD4(+) may therefore provide a novel prognostic predictor for HCC patients.
Biological roles and clinical applications of EpCAM in HCC.
Liu P, Zhang Q, Liu F Discov Oncol. 2025; 16(1):319.
PMID: 40087210 DOI: 10.1007/s12672-025-02095-0.
Ezrin Polarization as a Diagnostic Marker for Circulating Tumor Cells in Hepatocellular Carcinoma.
Budeyri I, Guckelberger O, Oppermann E, Roy D, Sliwinski S, Becker F Cells. 2025; 14(1.
PMID: 39791707 PMC: 11720075. DOI: 10.3390/cells14010006.
Novel biomarkers for monitoring and management of hepatocellular carcinoma.
Solhi R, Pourhamzeh M, Zarrabi A, Hassan M, Mirzaei H, Vosough M Cancer Cell Int. 2024; 24(1):428.
PMID: 39719624 PMC: 11668010. DOI: 10.1186/s12935-024-03600-1.
Hsu C, Liu Y, Huang J J Clin Transl Hepatol. 2024; 12(12):1020-1042.
PMID: 39649035 PMC: 11622199. DOI: 10.14218/JCTH.2024.00230.
Lu N, Sheng S, Xiong Y, Zhao C, Qiao W, Ding X Front Immunol. 2024; 15:1459740.
PMID: 39315112 PMC: 11416987. DOI: 10.3389/fimmu.2024.1459740.